Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Oct 03, 2006 by Edgar Snyder

Bayer Withheld Trasylol Study Findings

Trasylol

Last month, Bayer scientists met with the Food and Drug Administration (FDA) to discuss their heart-surgery drug, Trasylol, and its possible risks. But Bayer failed to mention that they already conducted a large study on the drug and the results showed an increase in the risk of death and stroke.

The study performed by Bayer evaluated 67,000 patient records. Of those, 30,000 received Trasylol and the rest got a different drug. The patients who received Trasylol had a greater risk of kidney failure, heart attack and stroke. A researcher involved in it alerted the FDA about the drug’s side-effects.

The FDA is evaluating the new study to find out whether the results will change the agency’s advice on the drug. Trasylol is given to patients prior to surgery to reduce the risk of blood loss and the need for transfusions in patients undergoing heart bypass surgery.

Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries
Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.

Source: “FDA Says Bayer Failed to Reveal Drug Risk Study.” By Gardiner Harris. The New York Times. September 30, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Tweet